SCHEMBL8769008

SCHEMBL8769008

Cc1ccc2c(C[C@@H](N)C(=O)O)c[nH]c2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.66
KDM4E B2RXH2 3/20 0.66
MAPT P10636 3/20 0.66
BLM P54132 3/20 0.66
LMNA P02545 2/20 0.66
TSHR P16473 2/20 0.66
PMP22 Q01453 2/20 0.66
MEN1 O00255 2/20 0.66
MPO P05164 1/20 0.66
HIF1A Q16665 1/20 0.66
PTPRA P18433 1/20 0.65
CYP2C19 P33261 1/20 0.62
HTR2A P28223 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
ALDH1A1 P00352 1/20 0.61
CYP3A4 P08684 1/20 0.61
HTR1A P08908 1/20 0.61
ADORA3 P0DMS8 1/20 0.61
ALOX15 P16050 1/20 0.61
NFKB1 P19838 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503548 1.00 KMT2A (0.66) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL29809822 1.00 KMT2A (0.66) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL31036029 1.00 KMT2A (0.66) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL503549 1.00 KMT2A (0.66) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL24113516 0.89 SCN9A (0.59) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL41266 0.89 KMT2A (0.73) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL30310502 0.89 SCN9A (0.59) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL16975865 0.89 HTR2A (0.55) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL41267 0.89 KMT2A (0.73) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL29527694 0.89 KMT2A (0.73) KMT2AKDM4EMAPTBLMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US claimed
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof RAYZEBIO, INC. (US) 2025-07-10 US disclosed
WO-2025137443-A1 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 WO disclosed
WO-2025137441-A1 RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 WO disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
CN-113861097-A Synthesis method of multi-configuration 1-Boc-N-Fmoc tryptophan compound 苏州爱玛特生物科技有限公司 2021-12-31 CN disclosed
EP-0443923-B1 New aminophosphine-phosphinites, their process and their use for enantio-selective reactions SANOFI SA (FR) 1997-08-27 EP disclosed
US-5210202-A Chiral phosphorous compounds, a process for their manufacture and their application to the catalysis of enantioselective synthesis reactions SOCIETE CHIMIQUE DES CHARBONNAGES S.A. (FR) 1993-05-11 US disclosed
US-5099077-A Dihydrocarbylphosphioxy substituted groups with amine or phosphinoamines as ligands SOCIETE CHIMIQUE DES CHARBONNAGES S.A. (FR) 1992-03-24 US disclosed
EP-0443923-A1 New aminophosphine-phosphinites, their process and their use for enantio-selective reactions SANOFI (FR) 1991-08-28 EP disclosed
US-4877908-A Chiral phosphorus compounds, a process for their manufacture and their application to the catalysis of enantioselective synthesis reactions NORSOLOR (FR) 1989-10-31 US disclosed
EP-0136210-B1 CHIRAL PHOSPHORUS LIGANDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE CATALYSIS OF ENANTIOSELECTIVE SYNTHESIS REACTIONS NORSOLOR S.A. (FR) 1989-08-16 EP disclosed
EP-0136210-A1 Chiral phosphorus ligands, process for their preparation and their use in the catalysis of enantioselective synthesis reactions NORSOLOR S.A. (FR) 1985-04-03 EP disclosed
US-4316847-A ARTIFICIAL SWEETENING HOFFMANN-LA ROCHE INC. (US) 1982-02-23 US disclosed
US-4256641-A ALKYL ALPHA-CARBOXAMIDOINDOLE-3-ACRYLATES MADE FROM 3-INDOLECARBOXALDEHYDES AND MONOALKYL CARBOXAMIDOMALONATES HOFFMANN-LA ROCHE INC. (US) 1981-03-17 US disclosed
US-4140697-A ARTIFICIAL SWEETENER HOFFMANN-LA ROCHE INC. (US) 1979-02-20 US disclosed
US-4073795-A Synthesis of tryptophans HOFFMANN-LA ROCHE INC. (US) 1978-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof SSTR2, SSTR4, SSTR5 KMT2A 1730/4885KDM4E 3869/4885MAPT 3475/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 KMT2A 3415/4885KDM4E 3586/4885MAPT 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.